Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
4,466 people get QCOR articles and Market Currents by email alert.
Get email alerts on QCOR »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Jun 11, 2013)
-
PR Newswire (Jun 10, 2013)
-
PR Newswire (May 29, 2013)
-
at MarketWatch.com (May 22, 2013)
-
PR Newswire (May 8, 2013)
-
at CNBC.com (Apr 30, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 15, 2013)
-
at CNBC.com (Mar 6, 2013)
-
PR Newswire (Feb 26, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Jan 3, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
PR Newswire (Jan 2, 2013)
-
at MarketWatch.com (Dec 27, 2012)
-
PR Newswire (Dec 4, 2012)
-
PR Newswire (Dec 3, 2012)
-
PR Newswire (Dec 3, 2012)
-
at CNBC.com (Nov 29, 2012)
QCOR vs. ETF Alternatives
Company Description
We market H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (“MS”), and the treatment of nephrotic syndrome.... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, October 8, 2012, 9:39 AM Questcor (QCOR +2.3%) rallies after SunTrust and Lazard respond positively to a UnitedHealth/Oxford policy update letter (.pdf) regarding Acthar gel coverage, which produced a selloff on Friday. SunTrust argues the update should reassure investors Acthar has value in treating nephrology and MS, while Lazard claims it's a positive given investor fears following Aetna's move to limit coverage. 40.3% of Questcor's float was shorted as of Sep. 14. 1 Comment [Healthcare, On the Move, Quick Ideas]
- Friday, October 5, 2012, 1:37 PM Questcor (QCOR -4%) trades lower after United Healthcare's Oxford Policy Update publishes revised Acthar approval timeframes , which limits the use of QCOR's Acthar Gel. 18 Comments [Healthcare, On the Move]
- Friday, September 28, 2012, 3:15 PM Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. ">inappropriate parallels " between Jazz Pharmaceutical's (JAZZ -0.4%) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. 8 Comments [Healthcare]
-
Friday, September 28, 2012, 9:10 AM
Premarket gainers: BYFC +42.86%. CYTX +18.91%. RIMM +15.83%. ASTX +8.71%. QCOR +9.03%.
Losers: ADTN -8.14%. CLWR -7.43%. PPHM -5.41%. 2 Comments - Friday, September 28, 2012, 8:36 AM Questcor Pharmaceuticals (QCOR) declares its first-ever quarterly dividend of $0.20/share. Forward yield 4.48%. For shareholders of record Oct 31. Payable Nov 15. Ex-div date Oct 29. Shares +8% premarket. (PR) 4 Comments [Dividends, On the Move]
-
Monday, September 24, 2012, 12:45 PM
Midday top 10 gainers: LMLP +82%. LPH +28%. BCOM +20%. RMBS +20%. SKBI +19%. VII +18%. AUDC +17%. CHOP +16%. COGO +15%. RMKR +13%.
Top 10 Losers: PPHM -77%. QCOR -33%. DLGC -15%. PAMT -12%. BIOF -11%. DHRM -11%. VECO -11%. CCM -10%. SRI -10%. BONA -10%. Comment! [On the Move] - Monday, September 24, 2012, 10:37 AM Wall Street reacts to Questor's (QCOR -28%) announcement of a government probe this morning, as a host of analysts lower their ratings. Oppenheimer downgrades the stock to Perform, Piper Jaffray cuts it to Neutral and Leerink Swann reduces it to Market Perform. Leerink cites more than just the federal probe, however, saying in its channel checks the reimbursement risks to Acthar are real. Comment! [Healthcare, On the Move]
-
Monday, September 24, 2012, 9:10 AM
Premarket gainers: LPH +39%. RMBS +13%. TIVO +10%. STSI +10%. HEB +8%. CPRX +6%.
Losers: PPHM -85%. QCOR -28%. GTAT -8%. FB -6%. AKS -5%. 1 Comment [On the Move] - Monday, September 24, 2012, 7:28 AM Shares of Questcor Pharmaceuticals (QCOR) plunge 19.5% premarket after the company discloses a government probe into its marketing practices. 3 Comments [Healthcare, On the Move]
- Friday, September 21, 2012, 2:38 PM Questcor Pharmaceuticals (QCOR +4.5%) continues to recover from Wednesday's dramatic drop of nearly 50%, as Roth Capital joins the chorus of analysts calling the reaction to the Aetna (AET) situation "overblown." QCOR's conference call yesterday "indicated that a highly-engaged and well-prepared reimbursement practice by QCOR has been successful and likely would continue as most cases are tightly sealed and more difficult for denial by insurers." the firm said in a note to clients. Comment! [Healthcare, On the Move]
- Thursday, September 20, 2012, 11:38 AM More on Questcor (QCOR +8.4%) conference call: COO Steve Cartt says insurance reimbursement for Acthar was already complicated before Aetna's (AET) coverage limitations, but QCOR is experienced in securing coverage for appropriate patients. "We anticipate that insurance coverage for Acthar will continue to be available" for the right patients." Comment! [Healthcare, On the Move]
- Thursday, September 20, 2012, 11:20 AM Questcor ((QCOR +13.4%)) swings back into the positive today in volatile trade on the back of its conference call currently in progress. Some highlights: CEO Don Bailey says it learned of Aetna's new policy only as of Wednesday; Prior authorizations are normal for Acthar, and it should not be used as a primary treatment to begin with; Acthar sales, prescription performance continues to improve. ( Webcast ). 5 Comments [Healthcare, On the Move]
- Wednesday, September 19, 2012, 12:35 PM Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's confirmed with Aetna (AET -0.3%) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written. 4 Comments [Healthcare, On the Move]
- Wednesday, September 19, 2012, 10:50 AM Shares of Questcor (QCOR) are now down 55% and halted on a circuit breaker. 3 Comments [Healthcare, On the Move]
- Wednesday, September 19, 2012, 10:31 AM Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron Research. Citron is saying that Aetna (AET -0.5%) has dropped almost all coverage of QCOR's drug Achtar for treating multiple sclerosis and nephrotic symdrome, saying that studies found no proof of efficacy to substantiate reimbursement. It will, however, continue to provide reimbursement when treating infantile spasms. 4 Comments [Healthcare, On the Move]
- Tuesday, September 18, 2012, 9:34 AM Oppenheimer raises its price target for Questcor Pharma (QCOR +3%) to $69 from $59 after positive commentary from investor meetings. Investors are becoming more comfortable with QCOR's perceived risks, the firm says, and any additional negative reports will result in limited downside volatility. Acthar reimbursement rates remain “extremely strong,” the firm adds. 2 Comments [Healthcare, Quick Ideas, On the Move]
-
- View all 0 replies
-
- View all 10 replies
-
techwonk: ...use your own judgment whether to hold or exit and re-enter... -
oneotherfool: It hasn't dipped below $25 since Dec. It's possible but I doubt it. I plan on holding & buying more below $27. Let's c what happens next wk.
-
oneotherfool
In a little over 2 weeks, $QCOR is down more than 14% for no real reasons. It's as if the great earning results never happened...load more? - View all 6 replies
-
Michael Webb: And in the further chance that additional fallout comes in the form of insurance companies rethinking reimbursement schedules, reason enuff? -
Michael Webb: Will these things happen? Probably not! BUT THAT IS WHY THE STOCK IS STUCK AT $32. Sorry. But that's the reason.
-
- View all 0 replies
-
- View all 5 replies
-
-
SKS1586: techwonk: Results are good with Joel Greenblatt's MFI Stocks (Warren Buffett Formula). Magic Diligence works exclusively with these stocks.
-
- View all 9 replies
-
PeterScriabin: you go to QCOR YMB (Yahoo Message Board) search on above terms, look for mikeylikesit33_99 posts = Michael Fuller. I did say "rumors" above. -
PeterScriabin: If we're talking $QCOR, have to assume we understand basics. Suggest reading posts of Maxdad, PharmaMan58, mikey. Way better YMB than most.
-
- View all 2 replies
-
gethigh: Yeah...plenty of shorts that have to cover. I'm still holding... -
-
StockConsultant
$QCOR getting close to a breakout above 33.55 with a good sized resistance gap, stock charts and analysis http://goo.gl/tPcK4 - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-
wecap: this stock is killing me. My Nov Calls sucking bug time. Should be a sec investigation. Shorts are spreading false rumors
-
- View all 6 replies
-
piggysun: Volume is very light, no worries. The upcoming conference might push it to 30
-
-
- View all 17 replies
-
TruffelPig: Looks like shorts are getting desperate. Someone made a ton of $$ on puts again. Hello SEC, where are you?
-
-
- View all 3 replies
-
eliaa123: The stock is so volatile that bad news travels like a wildfire. Two positive analyst actions this morning. ValuEngine and Leerink Swann. -
gethigh: Just too bad good news is considered a par while any bad "news" (emphasis on the "") is a triple bogey.
-
- View all 11 replies
-
-
-
FortSumter
Was at the gym and thought I saw QCOR at $58. Turned out it was QCOM. For a moment there I was in heaven. Ever happen to anyone else? - View all 4 replies
-
-
-
- View all 3 replies
-
-
Michael Webb: 30 is a nice target for year end. QCOR didn't help ease investor fears by eliminating monthly reports of product sales opting for quarterly
-
- View all 9 replies
-
FortSumter: @piggy - That's what I'm counting on. It's supposed to be a rather large divy if I remember.
-
-
- View all 4 replies
-
-
-
- View all 9 replies
-
-
Momintn: Buy on any dip. It will take a while for the shorts to realize they have to pay the dividend. Look up the pay date.
-
- View all 1 replies
-
andrilu_canubas: I will definitely hold this time... that cintron news recently scared me to death.. how I wish I never sold more than half of my position...
-
- View all 3 replies
-
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-